Advertisement

Interleukin Genetics Inc. (OTCQB: ILIU), which develops genetic testing for certain chronic conditions, on Wednesday reported year-over-year revenues of $799,000 and a net loss of $1.2 million for the second quarter of 2012, both of which are practically the same as the same period last year.

Advertisement
Advertisement